Personal information

Immuno-Oncology, Immunization and Infection Research
United States

Biography

Highly organized and hardworking professional with more than 10 years of wet lab research experience as well as over 11 years of leadership, management, and supervisory experience. Additional 18 years experience teaching with eight years as a certified instructor in various high-stress fields. Proficient in data collection and sample coordination for clinical and research trials. Excels in planning, implementing, managing, and evaluating protocols, policies, and projects. Excellent track record of effectively and efficiently communicating necessary information to required team members and presenting data and analyses to various teams, supervisors, collaborators, and sponsors.

Current research focused on the role of nitric oxide dependent processes in resistance to melanoma immune-based therapies. Recent research on the impact of the SARS-CoV-2 pandemic on cancer patients and the community, in addition to vaccine efficacy in those patients. Previous immunology research on the isolation and growth of Tumor Infiltrating Lymphocytes (TIL) and Peripheral Blood Mononuclear Cells (PBMCs) with T cell selection. Previous drug discovery research on small-molecule protein degradation and compound screening. Additional previous research utilizing Caenorhabditis elegans with focuses on anthropogenic compound toxicity, Alzheimer’s-type nerve degeneration and prevention, and establishment of a Parkinson’s-like phenotypic animal model.

Activities

Employment (2)

Moffitt Cancer Center: Tampa, Florida, US

2023-03 to present | Research Project Specialist (Center for Immunization and Infection Research in Cancer (CIIRC) / Immuno-Oncology)
Employment
Source: Self-asserted source
Christopher Dukes

Moffitt Cancer Center: Tampa, FL, US

2018-09 to 2023-03 | Research Associate (Immunology)
Employment
Source: Self-asserted source
Christopher Dukes

Education and qualifications (5)

University of South Florida: Tampa, FL, US

2019-05 | Graduate Certificate (Homeland Security)
Education
Source: Self-asserted source
Christopher Dukes

University of South Florida: Tampa, FL, US

2015-08 to 2019-05 | Master of Science (Medical Sciences)
Education
Source: Self-asserted source
Christopher Dukes

University of South Florida: Tampa, FL, US

2018-12 | Graduate Certificate (Infection Control)
Education
Source: Self-asserted source
Christopher Dukes

University of South Florida: Tampa, FL, US

2016-12 | Graduate Certificate (Health Sciences)
Education
Source: Self-asserted source
Christopher Dukes

Eckerd College: St. Petersburg, Florida, US

2009-08 to 2013-05 | Bachelor of Science with Honors (Biomedical Science)
Education
Source: Self-asserted source
Christopher Dukes

Professional activities (3)

Phi Sigma Theta, The National Honor Society: Tampa, Florida, US

2017-03 to present
Membership
Source: Self-asserted source
Christopher Dukes

Sigma Xi, The Scientific Research Society: St. Petersburg, Florida, US

2013-05 to present
Membership
Source: Self-asserted source
Christopher Dukes

Psi Chi International Honor Society in Psychology: St. Petersburg, Florida, US

2013-05 to present
Membership
Source: Self-asserted source
Christopher Dukes

Works (29)

Data from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Data from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Molecular Cancer Therapeutics
2024-08-01 | Journal article
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 4 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 4 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 6 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 6 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 7 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 7 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 8 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 8 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Table 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Table 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Table 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Table 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients

Vaccines
2023-12-22 | Journal article
Contributors: Christopher W. Dukes; Marine Potez; Jeffrey Lancet; Barbara J. Kuter; Junmin Whiting; Qianxing Mo; Brett Leav; Haixing Wang; Julie S. Vanas; Christopher L. Cubitt et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

SARS-CoV-2 antibody response duration and neutralization following natural infection

Journal of Clinical Virology Plus
2023-08 | Journal article
Contributors: Christopher W Dukes; Renata AM Rossetti; Jonathan A Hensel; Sebastian Snedal; Christopher L Cubitt; Michael J Schell; Martha Abrahamsen; Kimberly Isaacs-Soriano; Kayoko Kennedy; Leslie N Mangual et al.
Source: check_circle
Crossref

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients

Cancer Communications
2023-06-28 | Journal article | Author
Part of ISSN: 2523-3548
Part of ISSN: 2523-3548
Contributors: Anna Giuliano; Barbara Kuter; Shari Pilon‐Thomas; Junmin Whiting; Qianxing Mo; Brett Leav; Bradley Sirak; Christopher Cubitt; Christopher Dukes; Kimberly Isaacs‐Soriano et al.
Source: Self-asserted source
Christopher Dukes
grade
Preferred source (of 2)‎

Long-Term CD4<sup>+</sup> T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study

Vaccines
2022-11 | Journal article | Author
Contributors: Corey Gallen; Christopher Dukes; Amy Aldrich; Lauren Macaisa; QIANXING Mo; Christopher Cubitt; Shari Pilon-Thomas; Anna R. Giuliano; Brian Czerniecki; Ricardo Costa
Source: check_circle
Multidisciplinary Digital Publishing Institute

SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020–March 2021

Emerging Infectious Diseases
2022-03 | Journal article
Part of ISSN: 1080-6040
Part of ISSN: 1080-6059
Source: Self-asserted source
Christopher Dukes

Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida

JAMA Oncology
2022-03-10 | Journal article
Part of ISSN: 2374-2437
Source: Self-asserted source
Christopher Dukes